Elevated non-fasting triglycerides levels and remnant lipoprotein cholesterol content are considered independent biomarkers for cardiovascular risk assessment; indeed, genetic approaches on large populations have suggested their causal role in the development of atherosclerotic process, corroborating previous experimental evidences from in vitro studies and animal models. On top of data from basic and clinical research, it should be acknowledged that a person spends the majority of its time in postprandial phase; thereby lipid metabolism is a dynamic condition in which enzymatic activities, the structure, the half life and the content of circulating lipoproteins are continuously changing. Indeed, it is largely known that these parameters determine the atherogenicity of the same lipoproteins, which, during postprandial phase, activate key pathways of the atherosclerotic process. The elevated content in triglycerides and cholesterol in circulating lipoproteins, therefore, favor the diagnosis of “atherogenic dyslipidaemia”. Considering these aspects, it is easy to understand that this condition is not only significant for the clinical phenotype, but also for the response to pharmacological treatment and, finally, for the cardiovascular risk. Treatments of clinical use for dyslipidaemia are presently fibrates, niacin and omega-3. Both randomized trials and studies of postprandial kinetic confirmed their efficacy, on top of statins, even though contrasting data are not lacking, especially in high-risk patients. New therapeutic perspectives are therefore needed and studies of postprandial phase are useful to understand the physio-pathological mechanisms determining atherogenic dyslipidaemia. In the meanwhile, clinicians can obtain useful information to set more adequate therapies for each patient.

La lipemia postprandiale: dai risultati sperimentali all’intervento terapeutico = Postprandial lipemia: from experimental evidences to therapeutic treatment / A. Baragetti. - In: GIORNALE ITALIANO DI FARMACOECONOMIA E FARMACOUTILIZZAZIONE. - ISSN 2279-9168. - 8:2(2016), pp. 24-35.

La lipemia postprandiale: dai risultati sperimentali all’intervento terapeutico = Postprandial lipemia: from experimental evidences to therapeutic treatment

A. Baragetti
Primo
Writing – Review & Editing
2016

Abstract

Elevated non-fasting triglycerides levels and remnant lipoprotein cholesterol content are considered independent biomarkers for cardiovascular risk assessment; indeed, genetic approaches on large populations have suggested their causal role in the development of atherosclerotic process, corroborating previous experimental evidences from in vitro studies and animal models. On top of data from basic and clinical research, it should be acknowledged that a person spends the majority of its time in postprandial phase; thereby lipid metabolism is a dynamic condition in which enzymatic activities, the structure, the half life and the content of circulating lipoproteins are continuously changing. Indeed, it is largely known that these parameters determine the atherogenicity of the same lipoproteins, which, during postprandial phase, activate key pathways of the atherosclerotic process. The elevated content in triglycerides and cholesterol in circulating lipoproteins, therefore, favor the diagnosis of “atherogenic dyslipidaemia”. Considering these aspects, it is easy to understand that this condition is not only significant for the clinical phenotype, but also for the response to pharmacological treatment and, finally, for the cardiovascular risk. Treatments of clinical use for dyslipidaemia are presently fibrates, niacin and omega-3. Both randomized trials and studies of postprandial kinetic confirmed their efficacy, on top of statins, even though contrasting data are not lacking, especially in high-risk patients. New therapeutic perspectives are therefore needed and studies of postprandial phase are useful to understand the physio-pathological mechanisms determining atherogenic dyslipidaemia. In the meanwhile, clinicians can obtain useful information to set more adequate therapies for each patient.
Postprandial lipemia; Remnant lipoproteins; Atherogenic dyslipidaemia
Settore BIO/14 - Farmacologia
2016
http://www.sefap.it/web/upload/GIFF2016-2_24_35.pdf
Article (author)
File in questo prodotto:
File Dimensione Formato  
GIFF2016-2_24_35.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 297.67 kB
Formato Adobe PDF
297.67 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/718041
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact